MorphoSys shares rally according to CFO Lee
MorphoSys shares reacted to statements by CFO Sung Lee with strong price gains on Wednesday.
The stocks of the biotech company are currently increasing via XETRA by 6.98 percent to 35.70 euros, making them the front-runner in the SDAX. However, MorphoSys shares have been on a downward trend for many months. For the past year there is a minus of around two thirds.
“In 2025 we can have two drugs in hematological oncology on the market,” Lee told the Börsen-Zeitung. A year later, the company wants to be profitable and generate positive cash flow. “There is still a long way to go until 2026, but the optimistic tone could have a positive effect on sentiment,” commented a trader in the morning.
/ edh / jha /